Richard Saynor

Richard Saynor, CEO of Sandoz, dives deep into the ramifications of President Trump's proposed tariffs on imported pharmaceuticals. He outlines the minimal incentives for U.S. manufacturing and how these tariffs threaten the affordability and availability of generic drugs. Saynor also compares brand-name and generic companies, discussing the ethical dilemmas of rising costs for patients. He emphasizes the need for structural reforms in the generics industry as a critical step towards improving access to affordable medications in the shifting landscape of U.S. pharma.